Relay Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Relay TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 4.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 53.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -83.4% betragen.

Wichtige Informationen

-4.7%

Wachstumsrate der Gewinne

4.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	53.3%
Zukünftige Eigenkapitalrendite	-83.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:RLAY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	12	-453	-301	-364	8
12/31/2025	1	-415	-280	-329	12
12/31/2024	10	-360	-218	-211	12
9/30/2024	10	-345	-283	-280	N/A
6/30/2024	35	-323	-283	-281	N/A
3/31/2024	35	-329	-287	-284	N/A
12/31/2023	26	-342	-304	-300	N/A
9/30/2023	26	-326	-275	-268	N/A
6/30/2023	1	-344	-267	-259	N/A
3/31/2023	1	-323	-256	-247	N/A
12/31/2022	1	-291	-239	-229	N/A
9/30/2022	2	-290	-220	-212	N/A
6/30/2022	2	-267	-206	-199	N/A
3/31/2022	2	-384	-176	-170	N/A
12/31/2021	3	-364	-78	-74	N/A
9/30/2021	85	-261	-73	-70	N/A
6/30/2021	84	-414	-42	-41	N/A
3/31/2021	84	-247	-35	-34	N/A
12/31/2020	83	-230	-104	-102	N/A
9/30/2020	N/A	-289	-92	-90	N/A
6/30/2020	N/A	-95	-88	-83	N/A
3/31/2020	N/A	-86	-84	-78	N/A
12/31/2019	N/A	-75	-74	-66	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RLAY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RLAY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RLAY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RLAYDie Einnahmen des Unternehmens (53.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: RLAYDie Einnahmen des Unternehmens (53.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RLAY wird voraussichtlich in 3 Jahren unrentabel sein.

Relay Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 2,448%

Consensus revenue estimates decrease by 12%

Consensus revenue estimates increase by 10%

Price target decreased by 7.1% to US$22.87

Consensus revenue estimates increase by 1,470%

Consensus revenue estimates decrease by 10%

Recent updates

Relay Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Relay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000003 million.

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Relay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000003 million.

Relay Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Relay Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with Rly-2608

Consensus revenue estimates increase by 2,448%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

Relay Therapeutics, Inc., Annual General Meeting, Jun 03, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates decrease by 12%

Relay Therapeutics: Platform More Important Than Programs

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 10%

Relay Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

New major risk - Revenue and earnings growth

Relay Therapeutics, Inc. announced that it has received $30 million in funding

Relay Therapeutics, Inc. announced that it expects to receive $30 million in funding

Price target decreased by 7.1% to US$22.87

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 1,470%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Consensus revenue estimates decrease by 10%

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Relay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 8.4% to US$27.21

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.3% to US$29.04

Price target decreased by 12% to US$31.33

Consensus revenue estimates increase by 39%

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

CEO, President & Director exercised options and sold US$670k worth of stock

Chief Legal Officer & Secretary notifies of intention to sell stock

High number of new directors

CEO, President & Director exercised options and sold US$660k worth of stock

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings released: US$0.76 loss per share (vs US$0.66 loss in 3Q 2021)

President of Research & Development exercised options and sold US$149k worth of stock

Relay Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

CEO, President & Director exercised options and sold US$711k worth of stock

President of Research & Development exercised options and sold US$146k worth of stock

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Relay Therapeutics, Inc. Presents Data at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Relay Therapeutics, Inc. Presents Data at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Consensus revenue estimates fall by 20%

Why did Relay Therapeutics stock drop today?

President of Research & Development exercised options and sold US$153k worth of stock

President of Research & Development exercised options and sold US$313k worth of stock

Consensus forecasts updated

President of Research & Development exercised options and sold US$127k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Relay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Relay Therapeutics, Inc. Announces Appointment of Sekar Kathiresan to the Board

President of Research & Development exercised options and sold US$127k worth of stock